HALO

Halozyme Therapeutics Inc

HALO, USA

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

https://halozyme.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HALO
stock
HALO

Halozyme Elects James Lang to Board of Directors TipRanks

Read more →
HALO
stock
HALO

Tesla’s stock has an AI halo. Can Rivian’s get the same treatment? MarketWatch

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$76

Analyst Picks

Strong Buy

2

Buy

2

Hold

3

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

15.06

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

15.12

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

34.77 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

High

7.89 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

49.56 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

3.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 79.36% of the total shares of Halozyme Therapeutics Inc

1.

BlackRock Inc

(11.2854%)

since

2025/06/30

2.

Vanguard Group Inc

(10.4694%)

since

2025/06/30

3.

State Street Corp

(5.0742%)

since

2025/06/30

4.

iShares Core S&P Mid-Cap ETF

(3.4291%)

since

2025/08/31

5.

Vanguard Total Stock Mkt Idx Inv

(3.3125%)

since

2025/07/31

6.

Amvescap Plc.

(2.9632%)

since

2025/06/30

7.

Snyder Capital Management LP

(2.9049%)

since

2025/06/30

8.

Vanguard Small Cap Index

(2.5567%)

since

2025/07/31

9.

Arrowstreet Capital Limited Partnership

(2.1726%)

since

2025/06/30

10.

AllianceBernstein L.P.

(2.0991%)

since

2025/06/30

11.

Geode Capital Management, LLC

(2.0797%)

since

2025/06/30

12.

SPDR® S&P Biotech ETF

(1.8624%)

since

2025/08/31

13.

Macquarie Group Ltd

(1.7812%)

since

2025/06/30

14.

Bank of America Corp

(1.768%)

since

2025/06/30

15.

Dimensional Fund Advisors, Inc.

(1.7225%)

since

2025/06/30

16.

Congress Asset Management Company, LLP

(1.5692%)

since

2025/06/30

17.

Morgan Stanley - Brokerage Accounts

(1.5121%)

since

2025/06/30

18.

Vanguard Small Cap Growth Index Inv

(1.4422%)

since

2025/07/31

19.

UBS Group AG

(1.3033%)

since

2025/06/30

20.

GW&K Investment Management, LLC

(1.2179%)

since

2025/06/30

21.

Goldman Sachs Group Inc

(1.1693%)

since

2025/06/30

22.

Vanguard Explorer Inv

(1.1547%)

since

2025/06/30

23.

Charles Schwab Investment Management Inc

(1.1481%)

since

2025/06/30

24.

Caisse De Depot Et Placement Du Quebec

(1.1467%)

since

2025/06/30

25.

Vanguard Institutional Extnd Mkt Idx Tr

(1.1328%)

since

2025/07/31

26.

Stephens Inv Mgmt Group LLC

(1.1046%)

since

2025/06/30

27.

LSV Asset Management

(1.0732%)

since

2025/06/30

28.

Macquarie Small Cap Core I

(0.8451%)

since

2025/07/31

29.

SPDR® S&P MIDCAP 400 ETF Trust

(0.807%)

since

2025/07/31

30.

Stephens SMID Select Growth

(0.792%)

since

2025/06/30

31.

FullerThaler Behavioral Small-Cap Growth

(0.7023%)

since

2025/06/30

32.

iShares Russell Mid-Cap Growth ETF

(0.691%)

since

2025/08/31

33.

Invesco S&P MidCap Quality ETF

(0.6717%)

since

2025/08/29

34.

FullerThaler Behavioral Sm-Cp Gr R6

(0.6686%)

since

2025/07/31

35.

American Funds SMALLCAP World A

(0.6371%)

since

2025/06/30

36.

AB Intl Health Care AX USD

(0.6252%)

since

2025/07/31

37.

iShares Biotechnology ETF

(0.6214%)

since

2025/08/31

38.

T. Rowe Price Integrated US SmCapGrEq

(0.6199%)

since

2025/06/30

39.

T. Rowe Price Integrated US Sm Gr Eq

(0.6199%)

since

2025/07/31

40.

iShares S&P Mid-Cap 400 Growth ETF

(0.5992%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

1.72

EPS Estimate

1.61

EPS Difference

0.11

Surprise Percent

6.8323%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(10)
GARP
Fair GARP(6)
Growth
Moderate Growth(5.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(9)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.